Convergen Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$15M
- Investors
-
8
Convergen General Information
Description
Developer of an artificial intelligence-powered drug discovery platform designed to accelerate the research and development of therapeutic candidates. The company's platform offers generative biological models, antibody design, target discovery, biomarker identification, and protein optimization capabilities, enabling biotechnology and pharmaceutical companies to identify and develop promising drug candidates with reduced experimental effort.
Contact Information
Website
www.convergenbio.comCorporate Office
- Unit A3-5, Creative Industry Park, Number 328 Xinghu Street, Suzhou Industrial Park
- Suzhou Area of China Pilot Free Trade Zone
- Suzhou, 215000
- China
Corporate Office
- Unit A3-5, Creative Industry Park, Number 328 Xinghu Street, Suzhou Industrial Park
- Suzhou Area of China Pilot Free Trade Zone
- Suzhou, 215000
- China
Convergen Timeline
Convergen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A1) | 19-Aug-2026 | $15M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series A) | 26-Nov-2025 | Completed | Generating Revenue | |||
| 1. Seed Round | 16-Dec-2020 | Completed | Startup |
Convergen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Convergen Patents
Convergen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025252084-A1 | Pak4 bifunctional degraders, pharmaceutical compositions, and therapeutic applications | Pending | 04-Jun-2024 | ||
| WO-2025252084-A9 | Pak4 bifunctional degraders, pharmaceutical compositions, and therapeutic applications | Pending | 04-Jun-2024 | ||
| WO-2024120442-A1 | Pak4 protein degraders, pharmaceutical compositions, and therapeutic applications | Inactive | 07-Dec-2022 | A61P35/00 |
Convergen Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioTrack Capital | Venture Capital | Minority | ||
| GL Ventures | Venture Capital | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority | ||
| MPC (Beijing) | Venture Capital | Minority | ||
| Qiming Venture Partners | Venture Capital | Minority |
Convergen FAQs
-
When was Convergen founded?
Convergen was founded in 2020.
-
Where is Convergen headquartered?
Convergen is headquartered in Suzhou, China.
-
What industry is Convergen in?
Convergen’s primary industry is Discovery Tools (Healthcare).
-
Is Convergen a private or public company?
Convergen is a Private company.
-
What is Convergen’s current revenue?
The current revenue for Convergen is .
-
How much funding has Convergen raised over time?
Convergen has raised $25.5M.
-
Who are Convergen’s investors?
BioTrack Capital, GL Ventures, LAV (Lilly Asia Fund), MPC (Beijing), and Qiming Venture Partners are 5 of 8 investors who have invested in Convergen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
